Acinaris adenocarcinoma, Prosztatarák

Prostate adenocarcinoma cytology. Clinical Research News

Tartalom

    Leírás: 1.

    prostate adenocarcinoma cytology

    If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated. IP chemotherapy should not exceed total of 8 cycles.

    prostate adenocarcinoma cytology

    Karcsoport címke: Intraperitoneal paclitaxel with systemic chemotherapy Jogosultság Kritériumok: Inclusion Criteria: 1. Histologically or cytologically confirmed advanced gastric cancer adenocarcinoma 2.

    prostate adenocarcinoma cytology

    Age between 19 and 75 years 6. ECOG performance status 8.

    prostate adenocarcinoma cytology

    Should agree to use an adequate method of contraception Exclusion Criteria: 1. Patient who has distant metastasis or para-aortic lymph node metastasis or retroperitoneal metastasis except peritoneal metastasis. But the patient who has ovarian metastasis with resectable status can be enrolled. Primary tumor cannot be resected because of direct invasion to other important organ.

    prostate adenocarcinoma cytology

    But, if the invaded organ can be resected together, such as spleen, gallbladder, distal pancreas, and liver, the patient can be enrolled 4. Remnant gastric cancer 7.

    prostate adenocarcinoma cytology

    Intolerable to oral intake of chemotherapeutic agent or have malabsorption syndrome 8. Known additional malignancy that is progressing or requires active treatment in recent prostate adenocarcinoma cytology years excluding skin basal cell carcinoma, skin squamous cell carcinoma, thyroid cancer, or in situ cervix cancer that has undergone potentially curative therapy 9.

    Autoimmune disease in recent 2 years requiring systemic therapy Clinically significant heart disease Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through days after the last dose of trial treatment